KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Accured Expenses (2016 - 2025)

CRISPR Therapeutics AG's Change in Accured Expenses history spans 11 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 55.72% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $44.9 million, up 366.48%, while the annual FY2025 figure was $44.9 million, 366.48% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $4.4 million at CRISPR Therapeutics AG, down from $50.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $50.6 million in Q3 2025 and bottomed at -$37.8 million in Q4 2022.
  • The 5-year median for Change in Accured Expenses is $35500.0 (2024), against an average of $4.5 million.
  • The largest YoY upside for Change in Accured Expenses was 163032.26% in 2025 against a maximum downside of 2340.05% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $22.8 million in 2021, then tumbled by 265.85% to -$37.8 million in 2022, then surged by 129.55% to $11.2 million in 2023, then dropped by 10.58% to $10.0 million in 2024, then tumbled by 55.72% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Change in Accured Expenses are $4.4 million (Q4 2025), $50.6 million (Q3 2025), and $443000.0 (Q2 2025).